相似文献
1
Viral vector-mediated gene therapies.
Curr Opin Neurol. 2015 Oct;28(5):522-7. doi: 10.1097/WCO.0000000000000241.
2
Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy.
Mol Ther. 2018 Oct 3;26(10):2337-2356. doi: 10.1016/j.ymthe.2018.07.011. Epub 2018 Jul 17.
3
The AAV-mediated and RNA-guided CRISPR/Cas9 system for gene therapy of DMD and BMD.
Brain Dev. 2017 Aug;39(7):547-556. doi: 10.1016/j.braindev.2017.03.024. Epub 2017 Apr 5.
4
Perspective on Adeno-Associated Virus Capsid Modification for Duchenne Muscular Dystrophy Gene Therapy.
Hum Gene Ther. 2015 Dec;26(12):786-800. doi: 10.1089/hum.2015.107. Epub 2015 Oct 15.
5
Gene Therapy for Hemophilia and Duchenne Muscular Dystrophy in China.
Hum Gene Ther. 2018 Feb;29(2):146-150. doi: 10.1089/hum.2017.213.
6
Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression.
Mol Ther. 2007 Jun;15(6):1160-6. doi: 10.1038/sj.mt.6300161. Epub 2007 Apr 10.
7
Therapeutic Applications of CRISPR/Cas for Duchenne Muscular Dystrophy.
Curr Gene Ther. 2017;17(4):301-308. doi: 10.2174/1566523217666171121165046.
8
Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors.
Mol Ther. 2006 Feb;13(2):241-9. doi: 10.1016/j.ymthe.2005.11.001. Epub 2005 Dec 19.
9
Genetic therapeutic approaches for Duchenne muscular dystrophy.
Hum Gene Ther. 2012 Jul;23(7):676-87. doi: 10.1089/hum.2012.099.
10
Gene Therapy for Duchenne Muscular Dystrophy.
J Neuromuscul Dis. 2021;8(s2):S303-S316. doi: 10.3233/JND-210678.
引用本文的文献
1
Amelioration of Morphological Pathology in Cardiac, Respiratory, and Skeletal Muscles Following Intraosseous Administration of Human Dystrophin Expressing Chimeric (DEC) Cells in Duchenne Muscular Dystrophy Model.
Biomedicines. 2024 Mar 6;12(3):586. doi: 10.3390/biomedicines12030586.
2
Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review.
BioDrugs. 2024 Jan;38(1):95-119. doi: 10.1007/s40259-023-00632-3. Epub 2023 Nov 2.
3
Targeting Muscle-Resident Single Cells Through Electro-Enhanced Plasmid Transfer in Healthy and Compromised Skeletal Muscle.
Front Physiol. 2022 Apr 1;13:834705. doi: 10.3389/fphys.2022.834705. eCollection 2022.
4
Therapeutic Application of Extracellular Vesicles-Capsulated Adeno-Associated Virus Vector via , Satellite, and Immune Cells in Duchenne Muscular Dystrophy.
Int J Mol Sci. 2022 Jan 28;23(3):1551. doi: 10.3390/ijms23031551.
5
Current Pharmacological Strategies for Duchenne Muscular Dystrophy.
Front Cell Dev Biol. 2021 Aug 19;9:689533. doi: 10.3389/fcell.2021.689533. eCollection 2021.
6
Single-Use Capture Purification of Adeno-Associated Viral Gene Transfer Vectors by Membrane-Based Steric Exclusion Chromatography.
Hum Gene Ther. 2021 Sep;32(17-18):959-974. doi: 10.1089/hum.2019.284. Epub 2021 Mar 30.
7
Expressing a Z-disk nebulin fragment in nebulin-deficient mouse muscle: effects on muscle structure and function.
Skelet Muscle. 2020 Jan 28;10(1):2. doi: 10.1186/s13395-019-0219-9.
8
Functional rescue in a mouse model of congenital muscular dystrophy with megaconial myopathy.
Hum Mol Genet. 2019 Aug 15;28(16):2635-2647. doi: 10.1093/hmg/ddz068.
9
Utrophin up-regulation by artificial transcription factors induces muscle rescue and impacts the neuromuscular junction in mdx mice.
Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt A):1172-1182. doi: 10.1016/j.bbadis.2018.01.030. Epub 2018 Jan 31.
10
Spot light on skeletal muscles: optogenetic stimulation to understand and restore skeletal muscle function.
J Muscle Res Cell Motil. 2017 Aug;38(3-4):331-337. doi: 10.1007/s10974-017-9481-9. Epub 2017 Sep 16.
本文引用的文献
1
Functional disruption of the dystrophin gene in rhesus monkey using CRISPR/Cas9.
Hum Mol Genet. 2015 Jul 1;24(13):3764-74. doi: 10.1093/hmg/ddv120. Epub 2015 Apr 9.
2
AAV-8 is more efficient than AAV-9 in transducing neonatal dog heart.
Hum Gene Ther Methods. 2015 Apr;26(2):54-61. doi: 10.1089/hgtb.2014.128. Epub 2015 Apr 1.
3
Off-target-free gene delivery by affinity-purified receptor-targeted viral vectors.
Nat Commun. 2015 Feb 10;6:6246. doi: 10.1038/ncomms7246.
4
Intra-amniotic rAAV-mediated microdystrophin gene transfer improves canine X-linked muscular dystrophy and may induce immune tolerance.
Mol Ther. 2015 Apr;23(4):627-37. doi: 10.1038/mt.2015.5. Epub 2015 Jan 14.
5
Adeno-associated viral (AAV) vectors do not efficiently target muscle satellite cells.
Mol Ther Methods Clin Dev. 2014;1:14038-. doi: 10.1038/mtm.2014.38.
6
Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery.
Neurosurgery. 2015 Feb;76(2):216-25; discussion 225. doi: 10.1227/NEU.0000000000000589.
7
Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases.
Mol Ther. 2015 Mar;23(3):523-32. doi: 10.1038/mt.2014.234. Epub 2014 Dec 10.
8
Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9.
Stem Cell Reports. 2015 Jan 13;4(1):143-154. doi: 10.1016/j.stemcr.2014.10.013. Epub 2014 Nov 26.
9
Novel adeno-associated viruses derived from pig tissues transduce most major organs in mice.
Sci Rep. 2014 Oct 22;4:6644. doi: 10.1038/srep06644.
10
A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy.
Mol Ther. 2015 Jan;23(1):192-201. doi: 10.1038/mt.2014.200. Epub 2014 Oct 17.
Zotero 插件